GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 14, 2025
Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026
Read more at globenewswire.com0.7341
+0.03 (+4.13%)
Find more stocks in the Stock Screener
GTBP Latest News and Analysis
